World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
98
Citations
49024
World Ranking
772
National Ranking
439

Medicine

D-Index
99
Citations
50498
World Ranking
8438
National Ranking
4362

Henry F. McFarland publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Henry F. McFarland sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 346 publications — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Henry F. McFarland D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Henry F. McFarland sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 98 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Henry F. McFarland was affiliated with the National Institutes of Health in the United States. Their research primarily focused on medicine, with particular attention to pathology and forensic medicine, cell biology, oncology, nutrition and dietetics, and genetics.

The main topics covered in their work included multiple sclerosis research studies, skin and cellular biology research, polyomavirus and related diseases, trace elements in health, hemoglobinopathies and related disorders, endometrial and cervical cancer treatments, and the management of metastatic bone disease.

Frequent coauthors who collaborated with McFarland included Gary Cutter, Richard A. Rudick, Carl de Moor, Carol M. Singh, and Elizabeth Fisher.

Their publications appeared in several scientific venues. Notably, McFarland published in the following journals:

  • After Dinner Conversation
  • Multiple Sclerosis Journal - Experimental Translational and Clinical
  • American Journal of Neuroradiology
  • Neurology
  • International Journal of Radiation Oncology*Biology*Physics

A selection of recent papers authored or coauthored by McFarland includes:

  • Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial, 2023, Multiple Sclerosis Journal - Experimental Translational and Clinical
  • Manganese-Enhanced MRI in Patients with Multiple Sclerosis, 2020, American Journal of Neuroradiology
  • Serum neurofilament light-chain (sNfL) levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis (RRMS) patients in the CombiRx trial (2410), 2021, Neurology
  • Step Back, 2021, After Dinner Conversation
  • Sacrificing Mercy, 2022, After Dinner Conversation

Best Publications

  • Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis

    W. Ian McDonald;Alistair Compston;Gilles Edan;Donald E Goodkin

  • Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

    Chris H. Polman;Stephen C. Reingold;Gilles Edan;Massimo Filippi

  • Immunological aspects of demyelinating diseases

    Roland Martin;Henry F. McFarland;Dale E. McFarlin

  • Multiple sclerosis: a complicated picture of autoimmunity.

    Henry F McFarland;Roland Martin

  • Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.

    Bibiana Bielekova;Bonnie Goodwin;Nancy Richert;Irene Cortese

  • Differential diagnosis of suspected multiple sclerosis: a consensus approach

    D. H. Miller;B. G. Weinshenker;M. Filippi;B. L. Banwell

  • The role of magnetic resonance techniques in understanding and managing multiple sclerosis

    D H Miller;R I Grossman;S C Reingold;H F McFarland

  • Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases

    Kevin G. Becker;Richard M. Simon;Joan E. Bailey-Wilson;Boris Freidlin

  • Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis

    Bibiana Bielekova;Marta Catalfamo;Susan Reichert-Scrivner;Amy Packer

  • Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis.

    R Martin;H F McFarland

  • Multiple sclerosis (first of two parts).

    D E McFarlin;H F McFarland

  • Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA.

    Samantha S. Soldan;Rossana Berti;Nazi Salem;Paola Secchiero

  • Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients

    Paolo A. Muraro;Daniel C. Douek;Amy Packer;Katherine Chung

  • Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

    David Katz;Jeffery K. Taubenberger;Barbara Cannella;Dale E. McFarlin

  • Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial

    Jerry S. Wolinsky;Ponnada A. Narayana;Paul O'Connor;Patricia K. Coyle

  • Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals.

    Roland Martin;Dolores Jaraquemada;Marjorie Flerlage;John Richert

  • Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.

    Henry F. McFarland;Joseph A. Frank;Paul S. Albert;Mary E. Smith

  • Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.

    Jonathan O. Harris;Joseph A. Frank;Joseph A. Frank;Nicholas Patronas;Nicholas Patronas;Dale E. McFarlin

  • The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.

    Pascal Sati;Jiwon Oh;R. Todd Constable;Nikos Evangelou

  • The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

    Franz Fazekas;F. Barkhof;M. Filippi;R. I. Grossman

  • Identification of High Potency Microbial and Self Ligands for a Human Autoreactive Class II–restricted T Cell Clone

    Bernhard Hemmer;Burkhard T. Fleckenstein;Marco Vergelli;Günther Jung

Frequent Co-Authors

Roland Martin
Roland Martin University of Zurich
Dale E. McFarlin
Dale E. McFarlin National Institutes of Health
Joseph A. Frank
Joseph A. Frank National Institutes of Health
Steven Jacobson
Steven Jacobson National Institutes of Health
Bernhard Hemmer
Bernhard Hemmer Technical University of Munich
William E. Biddison
William E. Biddison National Institutes of Health
Bruno Gran
Bruno Gran University of Nottingham
Jerry S. Wolinsky
Jerry S. Wolinsky The University of Texas Health Science Center at Houston
Paul S. Albert
Paul S. Albert National Institutes of Health
Thomas A. Waldmann
Thomas A. Waldmann National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in studying Immunology in the USA, exploring related online degrees and career pathways can open doors to diverse healthcare opportunities. Many professionals in immunology-related fields come from nursing backgrounds and may consider advancing their qualifications through specialized programs.

Nurses looking to advance can explore an fnp to acnp bridge program online, which offers a focused transition from Family Nurse Practitioner to Acute Care Nurse Practitioner roles. This pathway provides targeted training relevant to critical care and immunological assessment.

For accelerated options, aspiring nurse practitioners might find value in accelerated np programs online, designed to fast-track clinical expertise, often integrating foundational immunological concepts.

Individuals without a nursing background can start with online bsn programs for non nurses that provide essential nursing education remotely, paving the way to immunology-related specialties later.

For those who want to enter the nursing field quickly, 12-month accelerated nursing programs offer condensed curricula, allowing students to rapidly acquire credentials necessary for careers involving immunological research or patient care.

Best Scientists Citing Henry F. McFarland

Recently Published Articles